Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Quantitative angiographic assessment of aortic regurgitation after transcatheter aortic valve implantation among three balloon-expandable valves
Global Heart, Volume 16, No. 1, Article 20, Year 2021
Notification
URL copied to clipboard!
Description
Objectives: The aim of the present analysis is to compare the quantitative angiographic aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) among three balloon-expandable valves. Background: Quantitative videodensitometric aortography is an objective, accurate, and reproducible tool for adjudication of AR following TAVI. Methods: This is a retrospective corelab analysis, independent from industry, of aortograms from patients treated with TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., India), Sapien 3, and XT THVs (Edwards Lifesciences, Irvine, CA, USA). The study comprised of 108 analyzable aortograms from consecutive patients in a multicenter European registry who underwent Myval THV implantation. The results of quantitative assessment of AR in the Sapien 3 THV (n = 397) and Sapien XT THV (n = 239) were retrieved from a published pooled database. Results: The Myval THV had the lowest proportion of patients with moderate or severe angiographic quantitative AR (2.8%) compared to the Sapien 3 THV (8.3%; p = 0.049) and Sapien XT THV (10.9%; p = 0.012). Furthermore, the Myval THV had the lowest mean angiographic quantitative AR (6.3 ± 6.3%), followed by Sapien 3 THV (7.6 ± 7.1%) and Sapien XT THV (8.8 ± 7.5%), and it was significantly lower than that of the Sapien XT THV (p = 0.006), but not significantly different from Sapien 3 THV (p = 0.246). Conclusion: The Myval THV, in comparison with other BEV's analyzed in our database, showed a lower occurrence of moderate or severe AR after TAVI. These results should be confirmed in prospective cohorts of randomized patients with head-to-head THV comparisons. © 2021 Elsevier B.V.. All rights reserved.
Authors & Co-Authors
Kawashima, Hideyuki
Ireland, Galway
University of Galway
Netherlands, Amsterdam
Universiteit Van Amsterdam
Wang, Rutao
Ireland, Galway
University of Galway
Netherlands, Nijmegen
Radboud University Medical Center
Mylotte, Darren M.
Ireland, Galway
University of Galway
De Marco, Federico
Italy, San Donato Milanese
Gruppo Ospedaliero San Donato
Ielasi, A.
Italy, Milan
Istituto Clinico Sant’ambrogio
Onuma, Yosinobu
Ireland, Galway
University of Galway
den Heijer, Peter
Netherlands, Breda
Amphia Hospital
Wijns, William C.
Ireland, Galway
University of Galway
Serruys, Patrick W.
Ireland, Galway
University of Galway
United Kingdom, London
Imperial College London
Soliman, O. I.I.
Ireland, Galway
University of Galway
Statistics
Citations: 15
Authors: 10
Affiliations: 9
Identifiers
Doi:
10.5334/gh.959
ISSN:
22118160
Study Design
Cohort Study
Study Approach
Quantitative